Southern California Research Center | Coronado, CA

Research site

(Unclaimed)

Location

131 Orange Avenue, Suite 101, Coronado, California, United States of America

Site insights

Top conditions

Top treatments

EDP-305

Ribavirin

TD-6450

Golimumab

BMS-650032

Daclatasvir

Cilofexor

BMS-790052

Semaglutide

Elafibranor

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 59 total trials

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC).Participants will also have inadequate response or intolerance t...

Enrolling

Primary Biliary Cholangitis (PBC)

Drug: Elafibranor

Other: Matched 80 mg placebo

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling

NASH

Cirrhosis, Liver

Drug: Resmetirom

Drug: Placebo

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling

Non-alcoholic Steatohepatitis (NASH)

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Placebo

Drug: ALN-HSD

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting

Crohn's Disease

Biological: JNJ-78934804

Biological: Golimumab

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC)

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting

Colitis, Ulcerative

Biological: JNJ-78934804

Drug: Placebo

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with...

Active, not recruiting

Hepatocellular Carcinoma

Drug: Nofazinlimab (CS1003)+Lenvatinib

Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling

PBC

Primary Biliary Cholangitis

Drug: Placebo

Drug: Volixibat

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling

Primary Sclerosing Cholangitis

Drug: Volixibat

Drug: Placebo

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative col...

Enrolling

Ulcerative Colitis

Drug: IV Placebo

Drug: SC Placebo

Locations recently updated

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to se...

Enrolling

Ulcerative Colitis

Drug: Placebo

Drug: Efavaleukin alfa

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% (APACHE)

This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum...

Enrolling

Acute-On-Chronic Liver Failure

Other: Standard Medical Treatment

Biological: SMT + PE-A 5%

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: PTM CILO/FIR

Drug: Cilofexor (CILO)/Firsocostat (FIR)

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis (PALEKONA)

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderat...

Enrolling

Ulcerative Colitis

Drug: Tilpisertib Fosmecarbil

Drug: Placebo

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis (PACIFIC)

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Scler...

Active, not recruiting

Pruritus

Drug: EP547

Drug: Placebo

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subj...

Enrolling

NON-ALCOHOLIC STEATOHEPATITIS

Drug: Sitagliptin

Drug: DA-1241 Placebo

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple asce...

Active, not recruiting

Primary Biliary Cholangitis

Drug: CNP-104

Drug: Placebo